Position:
Clinical Assistant Professor
Division:
Medical Oncology
Education:
B.Sc, McMaster University, Biochemistry
MD, University of Western Ontario
FRCPC, University of British Columbia, Medical Oncology
Recent Publications:
  • •Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill KK, et al.  The revised International Prognostic Index (R-IPI) is a Better Predictor of Outcome than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma treated with R-CHOP. Blood. 109(5):1857-61, 2007.
  • •Sehn LH, Donaldson J, Filewich A, Fitzgerald C, Gill KK, et al.  Rapid Infusion Rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood. 109(10):4171-73, 2007.
  • •Wilson KS, Sehn LH, Berry B, Chhanabhai M, Fitzgerald CA, Gill KK, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leukemia & Lymphoma. 48(6):1102-09, 2007.
  • •Al-Tourah AJ, Gill KK, et al.  Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin’s Lymphoma.  Journal of Clinical Oncology.  26(32):5165-69, 2008.
  • •Hui D, Lam W, Toze C, Delorme M, Noble M, Klimo P, Sutherland J, Gill K, et al.  Alemtuzumab in clinical practice: A British Columbia experience.  Leukemia & Lymphoma. 49(2):218-26, 2008.
  • •Al-Tourah AJ, Gill KK, et al.  Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin’s Lymphoma.  Journal of Clinical Oncology.  26(32):5165-69, 2008.
  • •Hui D, Lam W, Toze C, Delorme M, Noble M, Klimo P, Sutherland J, Gill K, et al.  Alemtuzumab in clinical practice: A British Columbia experience.  Leukemia & Lymphoma. 49(2):218-26, 2008.
  • •Farinha P, Al-Tourah A, Gill K, et al.  The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood. 115(2):289-95, 2010.